Zalicus Inc Com (NASDAQ:ZLCS)

CAPS Rating: 3 out of 5

A biopharmaceutical company pioneering the new field of synergistic combination pharmaceuticals, with a portfolio of product candidates in phase 2 clinical development.

Results 1 - 20 of 45 : 1 2 3 Next »

Recs

0
Member Avatar YoungNGunnin2 (24.28) Submitted: 1/24/2014 5:39:40 PM : Outperform Start Price: $1.66 ZLCS Score: -40.82

Technical Analysis:

I call this the panicked investor dramatic gap saucer with handle. Bull flag pullback actually forming a cup with handle. RECORD VOLUME SINCE SEPTEMBER compared to the last 5 years. Recently closing bullish the whole month of january on enormously above average volume. Buyers temporarily nervous. OBV on a very very very strong rise, RSI forming its own cup with handle. Closest Major resistance at $2.74-$3.00, 200 day MA resistance at about $3.25 which also matches up with gap resistance at about $3.75. As you can see there is plenty of room for profits between now and resistance. There is NO resistance in the immediate area so a quick profit leap is inevitable. Very few bears 3.65% shorting this stock and for good reason, they know this company has potential. there's more but eff you guys you don't take me seriously anyway.

News and company Analysis:

On november 11 2013 ONE of their pain drugs ended its PHASE 2(THATS IT?!?!) clinical trials early. Sending the stock plummeting to a low it's never seen before. People don't want to lose their money so the stock shoots downward and is still feeling the effects of one drug not hitting the correct receptor in the nervous system. So one of their drugs didn't work out very well. All it takes is a couple D bags to make the stock Gap down, hell anyone can make a stock gap up or down. Anyway, I'm not going to spend my time writing what this company actually does because last time I wrote a big story on what a company did no one rec'd or commented on it and the very next day both stocks I mentioned shot up over 15% each, and again over 10% again the next day. I know what the company does, how many drugs they have, what they target, and all that good stuff. But I'll try once more to gain some respect and recognition before I give up completely and just keep my ideas to myself. They are developing pain medication, Z944 which is probably going to start phase 2 testing. Instead of NUMBING the pain the medicine works as an inhibitor blocking pain receptors and receivers from telling your nervous system that you are in pain. Thats the jist of it from what I read and understand, if you want to find out for yourself go ahead and read on their website. I anticipate once they announce phase 2 people are going to cover their shorts and investors are going to hop back on the bandwagon.

Recs

1
Member Avatar jfogarty25 (32.22) Submitted: 11/26/2013 8:37:28 PM : Outperform Start Price: $1.30 ZLCS Score: -22.61

Chronic Pain meds that are not narcotics have HUGE potential. If this Z944 ever catches fire and works this could be a 10 bagger. Could also fail completely like Z160. Seems like they have enough other pipe line potential to warrant expectation of a low downside and large upside potential.

Recs

0
Member Avatar SqwiiTrader (43.40) Submitted: 11/19/2013 1:10:17 PM : Outperform Start Price: $1.07 ZLCS Score: -6.04

Buy when no one wants it ...

Recs

0
Member Avatar ptanabe (45.47) Submitted: 8/5/2013 2:23:47 PM : Outperform Start Price: $4.13 ZLCS Score: -82.99

k

Recs

0
Member Avatar TerryHoodSr (46.39) Submitted: 7/21/2013 1:25:27 AM : Outperform Start Price: $3.12 ZLCS Score: -75.72

growth

Recs

0
Member Avatar Sn8keiis (< 20) Submitted: 1/2/2013 8:29:03 AM : Outperform Start Price: $3.96 ZLCS Score: -100.93

Bargain price for a stock with HUGE potential. 1000 shares for less than a $1000 mitigates risk.

Recs

0
Member Avatar acumulator (< 20) Submitted: 8/20/2012 7:46:10 PM : Outperform Start Price: $7.56 ZLCS Score: -115.60

The potential for good news on there pain drug Synavive, could move the price of this stock up in the next several months which could make this a good trade.

Recs

0
Member Avatar slycat910 (68.61) Submitted: 8/16/2012 5:37:35 PM : Outperform Start Price: $8.28 ZLCS Score: -117.07

Nobody likes pain.

Recs

0
Member Avatar Fishboy1970 (< 20) Submitted: 6/23/2012 9:27:42 AM : Outperform Start Price: $7.62 ZLCS Score: -126.25

Just a hunch!

Recs

0
Member Avatar stevebkca09 (< 20) Submitted: 5/30/2012 6:26:14 PM : Outperform Start Price: $5.94 ZLCS Score: -122.51

Phase II trials will spark interest. Novartis partnership will likewise generate positive publicity and demand.

Recs

0
Member Avatar SamsaricSufferer (< 20) Submitted: 4/4/2012 4:37:48 PM : Outperform Start Price: $6.90 ZLCS Score: -117.23

Hard to miss at this price. Typical speculative biotech with typical speculative biotech issues. However.....ZLCS is priced post negative binary event, post dilutional stock issuance. Or to flip it around enough cash to fund operations for the near term (about 50M). Broad pipeline in clinical trial progression. Expanding revenue on Exalgo going forward to blunt burn rate.

Recs

0
Member Avatar RBuskey106 (55.20) Submitted: 4/4/2012 12:56:55 PM : Outperform Start Price: $6.84 ZLCS Score: -116.86

Chart Play

Recs

1
Member Avatar k2merlinsix (84.07) Submitted: 1/23/2012 9:48:04 AM : Outperform Start Price: $6.78 ZLCS Score: -124.32

ZLCS is growing their pipeline. The start of two Phase I ion drugs in addition to Synavive in Phase 2b and Prednisporin entering into Phase III studies for conjunctivits and lastly Novartis filling 3 patents and a pending 4th application that explicitly call out the use of ZLCSs cHTS technology shows plenty of momentum int his little stock and a very bright future as these drugs and partnerships mature.

Recs

0
Member Avatar DillonD (< 20) Submitted: 12/2/2011 11:12:46 AM : Outperform Start Price: $5.76 ZLCS Score: -128.67

Have potential to gain up to %400 in the short-term

Recs

0
Member Avatar thatkidfromseat (< 20) Submitted: 11/2/2011 3:36:00 PM : Outperform Start Price: $7.74 ZLCS Score: -135.23

Zalicus has an extreme amount of room for growth and has shown that they can successfully make a medical product in a somewhat limited market. If they stay the course, they could be a huge pick for those that take the risk

Recs

1
Member Avatar simischuster (< 20) Submitted: 10/29/2011 12:48:52 PM : Outperform Start Price: $7.68 ZLCS Score: -131.45

10% owner (MPM) has completed their planned sell of 3.5M shares from Sept '11. Stock has 10 analysts and avg 4.2 pps estimate. Zack's analyst PN has a you tube video that explains the story. Very well positioned for pain prevention market. Great pipeline and great partnerships.

Recs

1
Member Avatar kdb1952 (< 20) Submitted: 10/28/2011 10:18:06 PM : Outperform Start Price: $7.68 ZLCS Score: -131.45

i suffer from osteo arthritis and know many people who also suffer. the mere prospect of significant relief blows me away. if synavive is 1/2 what they are saying, it's pure gold! gotta go with z

Recs

0
Member Avatar Lcrazylegs84 (< 20) Submitted: 10/1/2011 1:04:35 AM : Outperform Start Price: $5.88 ZLCS Score: -146.23

going up

Recs

0
Member Avatar yurik515 (< 20) Submitted: 7/7/2011 2:31:41 AM : Outperform Start Price: $16.14 ZLCS Score: -129.90

Solid cash on hand, short term investment and cash equivalents, expanding drug pipeline, secured financing for future R&D programs, partnership with Sanofi and Novartis - all of these factors contribute to its (Zalicus) great long term story.

Recs

1
Member Avatar wiaggie (< 20) Submitted: 4/21/2011 12:20:05 AM : Outperform Start Price: $17.70 ZLCS Score: -131.86

Well run organization with a revenue-producing drug already in the marketplace and several new ones showing promise in the near future. Unlike many R&D firms, they also have cash-on-hand. Undervalued based on sheer assets, without even mentioning future earning potential.

Results 1 - 20 of 45 : 1 2 3 Next »

Featured Broker Partners


Advertisement